Clinical trial NCT03633110: Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Official title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cutaneous Melanoma
Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Urothelial Carcinoma
Renal Cell Carcinoma
Keywords: Vaccine
Personalized
Immunotherapy
Solid Tumor
Personal
Skin
Lung
Cancer
Bladder
Kidney
Melanoma
Carcinoma
Lead sponsor: Genocea Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2018-08-16
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A proprietary tool developed by Genocea, called ATLAS™ (Antigen Lead Acquisition System) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T cells. ATLAS-identified neoantigens will then be incorporated into a patient's personalized vaccine in the form of synthetic long peptides (SLPs).

Detailed description: This first-in-human study of GEN-009 will be conducted in two parts in adult patients with cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, or renal cell carcinoma (Part B only). In Part A, the safety and immunogenicity of single-agent GEN-009 will be evaluated in patients with the above-noted tumor types who have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy) and have no evidence of disease (NED) at the time of initiating vaccination with GEN-009. In Part B, up to 15 patients in each disease cohort will be enrolled and evaluated for safety, immunogenicity, and preliminary antitumor activity of GEN-009. Patients in Part B will receive GEN-009 at the schedule selected in Part A, in combination with a PD-1 inhibitor therapy (nivolumab or pembrolizumab) at the approved dose and schedule per the United States Package Insert (USPI). In addition, up to 15 patients who enroll in one of the Part B disease-specific cohorts but whose disease progresses during the screening period therapy may be enrolled into a separate relapsed/refractory disease cohort.

Eligibility criteria: General Inclusion Criteria:

* Diagnosis of 1 of the following tumor types:

  1. Melanoma (cutaneous).
  2. NSCLC.
  3. SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal).
  4. Urothelial carcinoma.
  5. Renal cell carcinoma (Part B only).
* Understand the study, be willing to comply with all study procedures and sign the informed consent
* Adequate tumor tissue available
* ECOG performance status of 0 or 1
* Negative pregnancy test (females of childbearing potential)
* Agree to use of contraception during the study until at least 90 days after final GEN-009 dose
* Adequate hematologic, liver, and kidney function

Part A-specific Inclusion:

* Have completed or will complete treatment for their disease with curative intent
* Have no evidence of disease

Part B-specific Inclusion:

* Receiving or will initiate treatment with nivolumab or pembrolizumab per disease as listed below:

  1. NSCLC: Patients with metastatic non-squamous NSCLC beginning first-line pembrolizumab in combination with pemetrexed and platinum chemotherapy, or metastatic squamous NSCLC beginning first-line pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel
  2. SCCHN: Patients beginning pembrolizumab with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy, or beginning first-line pembrolizumab for recurrent or metastatic SCCHN if tumors express PD-L1 with a Combined Positive Score (CPS) ≥ 1.
  3. Cutaneous Melanoma: Patients with unresectable or metastatic cutaneous melanoma beginning nivolumab monotherapy or nivolumab in combination with ipilimumab.
  4. Urothelial Carcinoma: Patients with locally advanced or metastatic urothelial carcinoma who are beginning pembrolizumab who:

     1. Are not eligible for cisplatin-containing chemotherapy, and tumor is PD-L1 positive with CPS ≥ 10, or are not eligible for any platinum-containing chemotherapy, OR
     2. Have had disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  5. Renal Cell Carcinoma:

     1. Patients with advanced RCC who have received prior anti-angiogenic therapy, and are beginning nivolumab monotherapy, OR
     2. Untreated patients with intermediate or poor risk RCC based on the IMDC score who are beginning nivolumab in combination with ipilimumab.
* Disease assessment by CT or MRI
* Have at least 1 lesion that is measureable by RECIST 1.1
* Agree to a tumor biopsy 50 days after first GEN-009 vaccination
* Participants with hypothyroidism must be on thyroid replacement treatment

General Exclusion Criteria:

* Received a live vaccine ≤ 28 days, or a non-live vaccine ≤ 14 days, prior to the first dose of GEN-009
* Acute or chronic skin disorders that would interfere with injection
* Receiving immunosuppressive therapies or systemic corticosteroids. Note: Use of topical corticosteroids or inhaled corticosteroids is acceptable
* Allergy to the vaccine adjuvant Hiltonol (poly-ICLC)
* Active hepatitis B or hepatitis C infection
* HIV Positive
* History of clinically significant cardiac condition
* History of leptomeningeal carcinomatosis
* Had clinically active immune-mediated disease within 5 years
* Received a prior allogeneic stem cell transplant
* Has primary immune deficiency
* Received a prior solid organ transplant
* Has malignant disease, other than the tumor types being treated in this study
* Female patient who is pregnant, breastfeeding, or who plans to become pregnant from the signing of the informed consent until ≥ 90 days from last dose of GEN-009
* Any condition that in the judgment of the PI would make the patient inappropriate for enrollment in the study
* Patient has received cytotoxic chemotherapy within 4 weeks of the first leukapheresis

Part A-specific Exclusion Criteria:

* Has received or requires more than 2 adjuvant or neoadjuvant regimens (other than surgical excisions) given with curative intent prior to first GEN-009 vaccination
* Has not recovered or stabilized from any clinically significant toxicity associated with any prior procedure or anticancer therapy

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: 1.5 years after first GEN-009 vaccination
measure: T-cell responses to GEN-009 adjuvanted vaccine
timeFrame: 1.5 years after first GEN-009 vaccination
Secondary outcomes:
measure: Antitumor activity of GEN-009 in Part B
timeFrame: 48 weeks after first GEN-009 vaccination
Other outcomes:
measure: Long-term clinical outcomes of Part A participants
timeFrame: 1.5 years after first GEN-009 vaccination
measure: Additional cellular responses after vaccination with GEN-009
timeFrame: 1 year after first GEN-009 vaccination
measure: Phenotype of circulating immune cells after vaccination with GEN-009
timeFrame: 1 year after first GEN-009 vaccination
measure: Tumor-infiltrating T cells after vaccination with GEN-009
timeFrame: 1 year after first GEN-009 vaccination
Locations:
city: La Jolla
country: United States
facility: UC San Diego Moores Cancer Center
state: California
city: Santa Monica
country: United States
facility: John Wayne Cancer Institute - Providence Saint John's Health Center
state: California
city: Aurora
country: United States
facility: University of Colorado, Anschutz Cancer Pavilion
state: Colorado
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
city: New York
country: United States
facility: Columbia University Medical Center - Herbert Irving Pavilion
state: New York
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
city: Nashville
country: United States
facility: The Sarah Cannon Research Institute
state: Tennessee
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Madison
country: United States
facility: University of Wisconsin Carbone Cancer Center
state: Wisconsin
Study officials:
name: Arthur P. DeCillis, MD
role: STUDY_DIRECTOR
References: